证券日报网讯 2月27日，昆药集团在互动平台回答投资者提问时表示，公司已于2023年制订中药说明书 安全项信息修订的计划，目前正按照计划积极推进相关工作。其中，昆中药蒲公英颗粒已完成了说明书 安全信息修订，杞菊地黄丸的说明书相关信息修订正在推进中。此外，公司已于2025年顺利完成昆中药 全部143个批准文号的药品再注册工作；并将持续推进相关药品说明书安全信息的修订，目标在下一个 再注册周期（2030年）前完成此项工作，并顺利获得再注册批件。根据现行法规要求，公司相关中药产 品目前均能正常上市销售。产品动销方面，近年来公司积极推进渠道重塑与品牌打造工作，对连锁终端 进行重点推广，同时持续优化全国零售渠道布局，进一步提升产品市场流通效率。 （文章来源：证券日报） ...

Core Viewpoint - The article explores the rich history and cultural significance of traditional Chinese medicine brand Tong Ren Tang, emphasizing its commitment to quality and community service over centuries [1][4][7]. Group 1: Company History and Philosophy - Tong Ren Tang was founded during the Kangxi era of the Qing Dynasty by Le Xianyang, initially named "Tong Ren Tang Pharmacy" [4]. - The brand has a legacy of over 357 years, known for its high-quality herbal medicines and adherence to traditional manufacturing principles [4][5]. - The motto "同修仁德 济世养生" reflects the company's dedication to benevolence and health care for the public [4][7]. Group 2: Product Offerings - The store offers a wide range of essential health products, including remedies for common ailments such as colds and digestive issues, particularly during the winter-spring transition [5][6]. - Classic formulas like Liu Wei Di Huang Wan and its variations are available, showcasing the brand's commitment to traditional Chinese medicine [6]. - The store also features a cultural section with creative products that appeal to tourists, enhancing the shopping experience [6]. Group 3: Community Engagement and Cultural Significance - Tong Ren Tang has a history of community involvement, such as providing lighting for safe passage home in the past, which has ingrained its name in the public consciousness [7]. - The company continues to support cultural initiatives, such as the "Tong Ren Literature Academy," fostering literary talent among youth [7]. - The upcoming live event aims to discuss the history and cultural impact of old brands like Tong Ren Tang, promoting traditional Chinese culture [8][9].

Core Viewpoint - The company has received a drug re-registration approval from the Anhui Provincial Drug Administration, which is crucial for the stability and continuity of its drug production and sales qualifications [1] Group 1 - The re-registration involves multiple products including Liuwei Dihuang Wan, Yuanhu Zhitong Capsules, and Qiju Dihuang Wan, with the approval valid until November 2030 [1] - This approval is expected to positively impact the company's future production, sales, and promotion efforts [1] - The company commits to strict compliance with production requirements to ensure product quality and provide high-quality products to the market [1]